Loading
A phase 1/2 trial of CTD402 CAR T Cell Injection in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Imviva Bio, now recruiting.
A Study of CTD402 in T-ALL/LBL Patients is a phase 1/2 interventional study registered as NCT07070219 by Imviva Bio, with 118 participants planned, started 2025-10-07 and due to reach its primary completion in 2028-09-30. Interventions recorded: CTD402 CAR T Cell Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/